Josep Carreras raises more than three million euros for the fight against leukaemia in the 22nd TV Gala in Germany.

• Dr. Albert Oriol, a hematologist at the Catalan Institute of Oncology/Germans Trias i Pujol Hospital, and researcher at the Josep Carreras Leukaemia Research Institute, takes part in an international study to assess a promising combination of drugs in the treatment of multiple myeloma.

• Multiple myeloma is still an incurable disease, but progress made over the last ten years has led to a very considerable improvement in the range of available treatments to combat it. One of these promising drugs is called daratumumab.

• In Spain there are 40 new cases of multiple myelomaper million inhabitants each year. 

Leukos Biotech, a biotechnology company founded by the Josep Carreras Leukemia Research Institute and by Dr. Ruth M. Risueño ​​will develop a novel class of drugs around a newly discovered therapeutic target that selectively destroys Leukemia Stem Cells. 

The third Saturday of each month of September we celebrate the World Blood Donor Day Marrow and Umbilical Cord Blood, an initiative of the World Marrow Donors Association (WMDA). Its a day to remind citizens around the world about the importance of donating bone marrow (hematopoietic stem cell or blood stem cells). (Available in Spanish).

On September 15th we celebrate the World Lymphoma Awareness Day. Is an important day becauselymphomas are the most common type of blood cancer. It is estimated that in Spain each year about 7,000 new cases are diagnosed. (more info in Spanish)

Raul Torres is a member of one of our research groups in our Campus Clínic-UB of the Josep Carreras Leukaemia Research Institute. He just received a support of the "Lady Tata Memorial Trust" to continue his project in our center. We want to know a little more about him and his work ...

Raul Torres is a member of one of our research groups in our Campus Clínic-UB of the Josep Carreras Leukaemia Research Institute. He just received a support of the "Lady Tata Memorial Trust" to continue his project in our center. We want to know a little more about him and his work ...